WO1999062315A3 - Method for altering the activity of proteins of the pka signaling pathway - Google Patents

Method for altering the activity of proteins of the pka signaling pathway Download PDF

Info

Publication number
WO1999062315A3
WO1999062315A3 PCT/GB1999/001680 GB9901680W WO9962315A3 WO 1999062315 A3 WO1999062315 A3 WO 1999062315A3 GB 9901680 W GB9901680 W GB 9901680W WO 9962315 A3 WO9962315 A3 WO 9962315A3
Authority
WO
WIPO (PCT)
Prior art keywords
altering
signaling pathway
activity
substrates
pka
Prior art date
Application number
PCT/GB1999/001680
Other languages
French (fr)
Other versions
WO1999062315A2 (en
Inventor
Vidar Hansson
Finn Olav Levy
Thomas Mustelin
Bjoern Steen Skaalhegg
Vibeke Sundvold
Kjetil Tasken
Torkel Vang
Amnon Altman
Anil Munshi
Original Assignee
Lauras As
Jones Elizabeth Louise
Vidar Hansson
Finn Olav Levy
Thomas Mustelin
Bjoern Steen Skaalhegg
Vibeke Sundvold
Kjetil Tasken
Torkel Vang
Amnon Altman
Anil Munshi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NO982419A external-priority patent/NO982419D0/en
Application filed by Lauras As, Jones Elizabeth Louise, Vidar Hansson, Finn Olav Levy, Thomas Mustelin, Bjoern Steen Skaalhegg, Vibeke Sundvold, Kjetil Tasken, Torkel Vang, Amnon Altman, Anil Munshi filed Critical Lauras As
Priority to AU41544/99A priority Critical patent/AU766674B2/en
Priority to EP99925154A priority patent/EP1080186A2/en
Priority to CA002333159A priority patent/CA2333159A1/en
Priority to NZ508359A priority patent/NZ508359A/en
Priority to JP2000551593A priority patent/JP2002516670A/en
Publication of WO1999062315A2 publication Critical patent/WO1999062315A2/en
Publication of WO1999062315A3 publication Critical patent/WO1999062315A3/en
Priority to NO20005939A priority patent/NO20005939L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/18—Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to methods of altering the activity of the PKA signaling pathway by altering, preferably inhibiting, the extent of phosphorylation of PKA substrates or downstream kinase substrates, particularly by the use of modified substrates, gene sequences encoding such modified substrates, vectors and host cells containing the gene sequence, inhibitors of substrate phosphorylation and use of the gene sequence, protein or inhibitors to alter the PKA signaling pathway, for example in treating immunosuppressive disorders or proliferative diseases.
PCT/GB1999/001680 1998-05-27 1999-05-27 Method for altering the activity of proteins of the pka signaling pathway WO1999062315A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU41544/99A AU766674B2 (en) 1998-05-27 1999-05-27 Method
EP99925154A EP1080186A2 (en) 1998-05-27 1999-05-27 Method for altering the activity of proteins of the pka signaling pathway
CA002333159A CA2333159A1 (en) 1998-05-27 1999-05-27 Method
NZ508359A NZ508359A (en) 1998-05-27 1999-05-27 Method of altering the activity of proteins of the PKA signalling pathway
JP2000551593A JP2002516670A (en) 1998-05-27 1999-05-27 Methods for altering protein activity of the PKA signaling pathway
NO20005939A NO20005939L (en) 1998-05-27 2000-11-24 Method for altering the activity of the proteins in the PKA signaling pathway

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NO982419A NO982419D0 (en) 1998-05-27 1998-05-27 Mutant enzymes and adapter molecules
NO19982419 1998-05-27
US11424098P 1998-12-30 1998-12-30
US60/114,240 1998-12-30

Publications (2)

Publication Number Publication Date
WO1999062315A2 WO1999062315A2 (en) 1999-12-02
WO1999062315A3 true WO1999062315A3 (en) 2000-05-04

Family

ID=26648845

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/001680 WO1999062315A2 (en) 1998-05-27 1999-05-27 Method for altering the activity of proteins of the pka signaling pathway

Country Status (6)

Country Link
EP (1) EP1080186A2 (en)
JP (1) JP2002516670A (en)
AU (1) AU766674B2 (en)
CA (1) CA2333159A1 (en)
NZ (1) NZ508359A (en)
WO (1) WO1999062315A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0501365D0 (en) 2005-01-21 2005-03-02 Promar As Compositions
GB0819883D0 (en) 2008-10-29 2008-12-03 Azyme Res As Product and uses
GB0921001D0 (en) 2009-11-30 2010-01-13 Aqua Bio Technology Asa Products and uses
GB0921525D0 (en) 2009-12-08 2010-01-27 Isis Innovation Product and method
GB201007202D0 (en) 2010-04-29 2010-06-16 Walther Bernt T Product and uses
GB201009271D0 (en) 2010-06-02 2010-07-21 Promar As Compositions
WO2014162962A1 (en) * 2013-04-01 2014-10-09 学校法人 久留米大学 Tumor antigen peptide
GB201909390D0 (en) 2019-06-28 2019-08-14 Univ Oxford Innovation Ltd TNF muteins and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019766A1 (en) * 1992-03-27 1993-10-14 The Regents Of The University Of California Methods and compositions for restoring impaired cellular immune function
WO1997011171A1 (en) * 1995-09-22 1997-03-27 Hybridon, Inc. Modified protein kinase a-specific oligonucleotides and methods of their use
WO1998048809A1 (en) * 1997-04-29 1998-11-05 Lauras As Use of immunomodulating agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019766A1 (en) * 1992-03-27 1993-10-14 The Regents Of The University Of California Methods and compositions for restoring impaired cellular immune function
WO1997011171A1 (en) * 1995-09-22 1997-03-27 Hybridon, Inc. Modified protein kinase a-specific oligonucleotides and methods of their use
WO1998048809A1 (en) * 1997-04-29 1998-11-05 Lauras As Use of immunomodulating agents

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ABRAHAM N. ET AL.: "Activation of p56lck through Mutation of a Regulatory Carboxy-Terminal Tyrosine Residue Requires Intact Sites of Autophosphorylation and Myristylation", MOLECULAR AND CELLULAR BIOLOGY, vol. 10, no. 10, October 1990 (1990-10-01), pages 5197 - 5206, XP000867882 *
HÄFNER S. ET AL.: "Mechanism of Inhibition of Raf-1 by Protein Kinase A", MOLECULAR AND CELLULAR BIOLOGY, vol. 14, no. 10, October 1994 (1994-10-01), pages 6696 - 6703, XP002130293 *
LALLI E. ET AL.: "Block of T lymphocyte differentiation by activation of the cAMP-dependent signal transduction pathway", THE EMBO JOURNAL, vol. 15, no. 3, 1 February 1996 (1996-02-01), pages 528 - 537, XP000867884 *
LIN K. ET AL.: "Targets of p56lck activity in immature thymoblasts: stimulation of the Ras/Raf/MAPK pathway", INTERNATIONAL IMMUNOLOGY, vol. 9, no. 2, February 1997 (1997-02-01), pages 291 - 306, XP000864380 *
SEVETSON B.R. ET AL.: "Increasing cAMP attenuates activation of mitogen-activated protein kinase", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 90, no. 21, 1 November 1993 (1993-11-01), pages 10305 - 10309, XP000867885 *
SUN G. ET AL.: "Csk Phosphorylation and Inactivation in Vitro by the cAMP-Dependent Protein Kinase", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 343, no. 2, 15 July 1997 (1997-07-15), pages 194 - 200, XP002121306 *
TAMIR A. ET AL.: "Inhibition of T Lymphocyte Activation By cAMP Is Associated with Down-Regulation of Two Parallel Mitogen-Activated Protein Kinase Pathways, the Extracellular Signal-Related Kinase and c-Jun N-Terminal Kinase", THE JOURNAL OF IMMUNOLOGY, vol. 157, no. 4, 15 August 1996 (1996-08-15), pages 1514 - 1522, XP002121305 *
TURNER M. ET AL.: "A Requirement for the Rho-Family GTP Exchange Factor Vav in Positive and Negative Selection of Thymocytes", IMMUNITY, vol. 7, no. 4, October 1997 (1997-10-01), pages 451 - 460, XP000864365 *

Also Published As

Publication number Publication date
NZ508359A (en) 2003-07-25
WO1999062315A2 (en) 1999-12-02
AU766674B2 (en) 2003-10-23
AU4154499A (en) 1999-12-13
JP2002516670A (en) 2002-06-11
CA2333159A1 (en) 1999-12-02
EP1080186A2 (en) 2001-03-07

Similar Documents

Publication Publication Date Title
WO2003089457A3 (en) Peptide inhibitors of protein kinase c ϝ for pain management
Takahashi-Nakamura et al. Purification and characterization of an inhibitor of calcium-activated neutral protease from rabbit skeletal muscle
WO2003016475A3 (en) Nucleic acid and amino acid sequences involved in pain
MX9709442A (en) Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions.
CA2471762A1 (en) Cell-permeable peptide inhibitors of the jnk signal transduction pathway
WO2001070977A3 (en) Fibroblast growth factor receptor-like molecules and uses thereof
WO1999062315A3 (en) Method for altering the activity of proteins of the pka signaling pathway
WO2001068854A3 (en) Fibroblast growth factor-like molecules and uses thereof
AU6724794A (en) GRB3-3 gene, its variants and their uses
HK1041289A1 (en) Methods and compositions useful for modulation of angiogenesis using tyrosine kinase src
AU2001289034A1 (en) Novel pdes and uses thereof
WO2002040683A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2003048303A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002016567A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002053717A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2001088148A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002091926A3 (en) Inhibitors of dna methyltransferase isoforms
WO2002072753A3 (en) Thymidylate synthase peptides that bind to thymidylate synthase messenger rna
WO2001090328A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002068617A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2003038115A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2000065055A3 (en) Human transporter proteins
WO2002036741A3 (en) Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme
WO2003095612A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002079431A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 41544/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 508359

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2333159

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09722845

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1999925154

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999925154

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 41544/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999925154

Country of ref document: EP